Aravive Inc

Aravive — Investor Presentation (July 2020)

29 slides from Aravive's investor presentation, Jul 23, 2020

  1. Slide 1: Corporate Presentation July 2020: Halting Disease Progression in its Tracks

    © 2020 Aravive, Inc. Corporate Presentation July 2020 Halting Disease Progression in its Tracks Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    © 2020 Aravive, Inc. Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking statements generally i

  3. Slide 3: Company Overview

    © 2020 Aravive, Inc. Aravive is a clinical stage company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Nasdaq-listed company (ARAV) Offices in Houston, TX (HQ) and RTP, NC $20 million Product Development Award from the Cancer Prev

  4. Slide 4: AVB-500: Lead Clinical Program

    © 2020 Aravive, Inc. A first-in-class, ultra-high affinity, Fc-fusion protein designed to selectively block the novel GAS6-AXL signaling pathway Proof-of-mechanism established in clinic using proprietary biomarker for target engagement Early proof-of-concept for anti-tumor activity demonstrated in p

  5. Slide 5: Pipeline Focused on GAS6/AXL Signaling in Oncology

    © 2020 Aravive, Inc. Indication Preclinical 3rd Oncology (undisclosed indication) Status: IND Open Status: Recruiting Status: Recruiting Phase 1 Phase 3 Phase 2 Phase 2a Phase 2b Anti-CTGF AVB-500 IST with AstraZeneca Ovarian Cancer platinum resistant (PAC or PLD combination) Ovarian Cancer platinum

  6. Slide 6: GAS6/AXL Pathway is Critical in Cancer Biology and Promotes Invasion, Metastasis

    AXL is a member of tyrosine kinases that include Tyro3, AXL, and Mer (TAMs) AXL is activated by a single ligand, growth arrest– specific 6 (GAS6); Mer and Tyro3 can be activated by GAS6 and Protein S 1 Upregulated in many cancers 2, AXL overexpression linked to metastasis 3 ,4, poor survival 5-7, an

  7. Slide 7: Engineered Decoy Receptor is the Best Approach for GAS6/AXL Inhibition

    © 2020 Aravive, Inc. AVB-500 Decoy has fM Affinity to neutralize GAS6 Selectivity limited by RTK homology Off-target toxicity Multiple resistance mechanisms Many potential competitors Requires a mAB affinity that competes with receptor Not achievable for AXL Many potential competitors Binds more tig

  8. Slide 8: Other Drugs Targeting AXL Signaling in Clinical Development are Not Selective

    © 2020 Aravive, Inc. DRUG (STAGE) COMPANY TARGET SELECTIVE FOR AXL AVB-500 (Ph Ib/II) Aravive GAS6 YES gilteritinib (Market; AML) Astellas AXL (Multi-kinase) NO cabozantinib (Market; RCC & HCC) Exelixis AXL (Multi-kinase) NO sitravatinib (Ph III) Mirati (BeiGene) AXL (Multi-kinase) NO merestinib (Ph

  9. Slide 9: Phase 1b Study Design

    © 2020 Aravive, Inc. AVB-500 (AVB): q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m2 d1 28-day cycle paclitaxel (PAC): 80 mg/m2 day 1, day 8, day 15; Maintenance dosing on AVB-500 monotherapy AVB 500 10 mg/kg + PLD AVB 500 15 mg/kg + PLD Select RP2D AVB 500 10 mg/kg + PAC AVB 500 15 mg/kg + P

  10. Slide 10: Overall Phase 1b Baseline Characteristics and Demographics

    Overall Phase 1b Baseline Characteristics and Demographics 10 MG/KG PER PROTOCOL COHORT AVB+PAC AVB+PLD OVERALL AGE, YEARS n 23 30 53 Mean 63.95 64.32 64.16 HISTOLOGY AT DIAGNOSIS Adenocarcinoma NOS 2 (8.7%) 1 (3%) 3 (5.7%) High-grade Endometroid Adenocarcinoma 1 (4.3%) 1 (3%) 2 (3.7%) High-grade Se

  11. Slide 11: Safety Data Summary from Phase 1b Study

    Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reported AE severity and frequency are consistent with expectations of the concomitant treatment (PAC or PLD) and th

  12. Slide 12: AVB-500 Phase 1b Study: RP2D is 15 mg/kg

    Trough levels statistically significantly correlate with response and prolonged PFS Updated modeling with actual PK data shows 59%, 84% and 93% of patients are expected to achieve minimal efficacious concentration (MEC) at 10 mg/kg, 15 mg/kg, 20 mg/kg, respectively PK appears to plateau at 15 mg/kg

  13. Slide 13: Response Higher in PAC than Historical Data

    INVESTIGATOR-ASSESSED BEST RESPONSE PER RECIST V1.1 PAC (N=23) PLD (N=26) CR 2 (8.7%) 0 PR 6 (26%) 4 (15%) ORR 8 (35%) 4 (15%) SD 6 (26%) 12 (46%) CBR 14 (61%) 16 (61.5%) PD 9 (39%) 10 (38.5%) 1 A. Davis et al. / Gynecologic Oncology 133 (2014) 624–631 Response Higher in PAC than Historical Data of

  14. Slide 14: Improved Clinical Benefit in Later Lines of Therapy

    CLINICAL RESPONSE OF AVB-500+CHEMO IN 3L AND 4L CLINICAL RESPONSE OF CHEMOTHERAPY IN 3L AND 4L PER BRUCHIM ET AL, 2013 (N=99) 34 patients in AVB-500+chemo group overall; 20 patients in the high exposure AVB-500+chemo group; Two CRs in High Exposure Category Updated analysis based on all per protocol

  15. Slide 15: Improved Clinical Benefit in Patients with PFI < 3 Months

    Updated analysis based on all per protocol patients CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS WITH <3MO PFI PER KOBAYASHI-KATO ET AL, 2019 (N=21) CLINICAL RESPONSE OF AVB-500+CHEMO IN PATIENTS WITH <3MO PFI ORR= objective response rate; SD=stable disease; CBR=clinical benefit rate; PD=progressiv

  16. Slide 16: Phase 1b Response Results by Dose Cohort

    10 mg/kg cohort, 37 out of 40 patients evaluable: 31% ORR (5/16) in combination with PAC, 1 complete response (CR) 50% ORR (4/8), with 1 CR in PAC patients achieving MEC of AVB-500 mPFS 7.5 months versus 2.28 months for those achieving MEC vs. those below MEC (p=0.0062) 21.6% ORR (8/37) in all evalu

  17. Slide 17: Phase 1b Findings Aid Phase 2/3 Trial Design

    AVB-500 has better activity in: Combination with PAC Patients whose C1D15 trough level >13.8mg/L Patients who have not previously been treated with bevacizumab Patients with high baseline sAXL/GAS6 ALL INDEPENDENT OF EACH OTHER Phase 1b Findings Aid Phase 2/3 Trial Design © 2020 Aravive, Inc.

  18. Slide 18: AVB-500 Combined with Paclitaxel Showed Better Responses in High Exposure Group

    AVB500 + PACLITAXEL ABOVE MEC BELOW MEC Number of Patients (n) 14 9 Complete Response (CR) 2 (14%) 0 Partial Response (PR) 4 (28%) 2 (22%) Overall Response Rate (ORR) 6 (43%) 2 (22%) Stable Disease (SD) 3 (21%) 3 (33%) Clinical Benefit (SD+ORR) 9 (64%) 5 (55%) Progressive Disease (PD) 5 (36%) 4 (45%

  19. Slide 19: Significant Improvement of mPFS in Patients with High Drug Exposure

    Blue = above 13.8 mg/L Red = below 13.8 mg/L AVB-500+ PAC AVB-500+ PAC or PLD Significant Improvement of mPFS in Patients with High Drug Exposure More Pronounced in 10mg/kg AVB-500 +PAC vs. PLD © 2020 Aravive, Inc.

  20. Slide 20: % Change in Target Lesions at Best Response by AVB Dose Level

    49 pts in per protocol population, no quantitative CT data for 08-0001 (patient shown on x-axis all the way to right in figure); 4 pts with target lesions that were stable were determined to be PD as best response 10 mg/kg 15 mg/kg 20 mg/kg Target lesions in ~70% patients were stable (i.e, w/in +20

  21. Slide 21: Duration of Treatment by Trough above MEC

    Days 50 100 150 200 250 300 350 * * * # # Trough above MEC Trough below MEC Per protocol population * Still on study # on AVB-500 alone after 6 mos chemo # Duration of Treatment by Trough above MEC: Patients with Higher Exposures Stayed on Treatment Longer © 2020 Aravive, Inc.

  22. Slide 22: Third-Party Historical Data as Benchmark (AURELIA Study)

    AVB-500 + PAC PRIOR BEVACIZUMAB No Yes N 10 13 CR 2 (20%) 0 PR 4 (40%) 2 (15%) ORR 6 (60%) 2 (15%) SD 1 (10%) 5 (38%) CBR 7 (70%) 7 (54%) PD 3 (30%) 6 (46%) 1 Journal of Clinical Oncology, Vol 33, No 32 (November 10), 2015: pp 3836-383 Third-Party Historical Data as Benchmark (AURELIA Study1) Subgro

  23. Slide 23: Potential Biomarker: Baseline Serum sAXL/GAS6

    sAXL/GAS6 >0.773 Yes NO N 14 7 CR 2 (14%) 0 PR 4 (28%) 0 ORR 6 (43%) 0 SD 2 (14%) 4 (57%) CBR 8 (57%) 4 (57%) PD 6 (43%) 3 (43%) sAXL not available for 2 patients Similar results seen in PLD combination Serum levels of sAXL/GAS6 ratio in a post-hoc analysis correlated with response to AVB-500 + chem

  24. Slide 24: Planned Phase 2/3 Trial

    Potential Registrational Study Primary objective to assess anti-tumor activity of AVB-500 in combination with PAC as measured by PFS FDA’s preliminary feedback Current RCT design is expected to be appropriate Investigating adaptive designs / interim analyses exploring potential biomarkers or alterna

  25. Slide 25: 2020 Milestones

    2Q 2019 – POM in Ovarian Cancer 2Q 2019 – Tolerability in Ovarian Cancer 3Q 2019 – Early POC in Ovarian Cancer 3Q 2019 – Expanded P1b Ovarian Cancer 4Q 2019 – IgAN Initiated* 1Q 2020 – IND open for ccRCC study Mid-2020 – Safety and PK from Ph1b PROC 2H 2020/Q1 2021 – P2/P3 PROC initiation 2H 2020 –

  26. Slide 26: Growth Strategy: Strengthen Company and Build Pipeline

    Expand Board of Directors Opportunistic with respect to business development deals around our pipeline ex-U.S. Focus on oncology: Advance PROC Phase 2/3 trial Initiate ccRCC trial Potential pipeline expansion in high unmet oncology indications, all of which GAS6/AXL pathway is active and relates to

  27. Slide 27: Financials and Capitalization

    © 2020 Aravive, Inc. NASDAQ: ARAV; Shares Outstanding*: 15.0M basic Cash and cash equivalents*: $61M Cash and cash equivalents expected to enable the company to fund its current operating plans into 2022, depending on PROC P2/P3 design * As of March 31, 2020 Financials and Capitalization

  28. Slide 28: Uniquely positioned in competitive landscape

    © 2020 Aravive, Inc. Uniquely positioned in competitive landscape Robust pipeline addressing significant drivers of mortality in oncology: metastasis and drug resistance AVB-500: high affinity decoy protein, a potent and selective drug that targets GAS6/AXL signaling Validated pathway drives activat

  29. Slide 29: Thank You

    © 2020 Aravive, Inc. Thank You Halting Disease Progression in its Tracks

Aravive — Investor Presentation (July 2020) on 6ix